Sironax has recently completed its Phase I clinical trial for SIR2501, an innovative drug candidate with potential to treat neurodegenerative and other neurological diseases. This was a randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study to assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of SIR2501 in healthy volunteers. The trial was conducted primarily in Australia with a bridging cohort in China.
Sironax team is excited with the Phase I results, which align with preclinical expectations and support the advancement of SIR2501 into patient studies. The complete data analysis will be presented at upcoming medical conferences and/or through peer-reviewed clinical publications.
Preclinical studies have demonstrated SIR2501’s neuroprotective effects in models of amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, and other conditions. Building on preclinical findings and the Phase I results, Sironax is planning to advance SIR2501 into patient studies soon for neurological disorders, an area with significant medical unmet need. .
About Sironax
Sironax is a clinical-stage biotechnology company dedicated to the discovery and global development of novel treatments for age-related degenerative diseases. Since its founding in 2017, Sironax has built a diverse pipeline of multiple programs focusing on key mechanisms underlying age-related degenerative diseases, including dysregulated cellular death, uncontrolled inflammation, and disrupted energy homeostasis. Sironax is currently conducting clinical studies with SIR2501, SIR4156, and SIR9900, in addition to ongoing preclinical research. The company was named to the 2025 Endpoints 11 list of the most promising biotech startups.